{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:25:20Z","timestamp":1773746720089,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1007\/s12325-019-0873-7","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T11:28:41Z","timestamp":1550057321000},"page":"950-961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed\/Refractory Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"36","author":[{"given":"Jinlin","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Belton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"873_CR1","doi-asserted-by":"crossref","unstructured":"Jabbour EJ, Stefan Faderl, and Hagop M. Kantarjian. Adult acute lymphoblastic leukemia. Mayo Clinic Proce. 2005;80(11):1517\u201327.","DOI":"10.4065\/80.11.1517"},{"key":"873_CR2","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.","journal-title":"Blood Cancer J."},{"key":"873_CR3","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: Blinatumomab for the treatment of acute lymphoblastic leukemia. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500005882.pdf. Accessed 19 Sep 2017."},{"issue":"8","key":"873_CR4","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025\u201337.","journal-title":"Blood"},{"issue":"10","key":"873_CR5","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","volume":"20","author":"C Linker","year":"2002","unstructured":"Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(10):2464\u201371.","journal-title":"J Clin Oncol"},{"issue":"3","key":"873_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood"},{"issue":"3","key":"873_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863\u201371.","journal-title":"Blood"},{"issue":"4","key":"873_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95(4):589\u201396.","journal-title":"Haematologica"},{"issue":"12","key":"873_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333.","journal-title":"Haematologica"},{"key":"873_CR10","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia. 2018. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed 24 Apr 2018"},{"key":"873_CR11","unstructured":"United States Food and Drug Administration. Highlights of prescribing information- BLINCYTO. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125557s008lbl.pdf. Accessed 12 Apr 2018."},{"key":"873_CR12","unstructured":"European Medicines Agency. Blincyto. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003731\/WC500198229.pdf. Accessed 12 Apr 2017."},{"issue":"9","key":"873_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus Chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"key":"873_CR14","unstructured":"European Medicines Agency. Assessment report: Besponsa. 2018. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004119\/WC500231263.pdf. Accessed 24 Apr 2018"},{"key":"873_CR15","unstructured":"Stelljes M, Su Y, Fahrbach K, Vandendries E, Page V, Onyekwere U, et al. Indirect treatment comparison of inotuzumab ozogamicin and blinatumomab for relapsed or refractory acute lymphoblastic leukemia. In: Presented at American Society of Hematology (ASH) annual meeting on December 9\u201312, 2017 at Atlanta, GA."},{"key":"873_CR16","unstructured":"Kantarjian Hea. Inotuzumab ozogamicin vs standard of care in patients with relapsed\/refractory acute lymphoblastic leukemia: long-term results of the phase 3 INO-VATE study. In: Presented at 59th American Society of Hematology (ASH) annual meeting on September 9\u201312, 2017 at Atlanta, GA."},{"key":"873_CR17","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: BESPONSA. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Accessed 12 Apr 12 2018."},{"issue":"8","key":"873_CR18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"873_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-2141.2010.08246.x","volume":"150","author":"JM Rowe","year":"2010","unstructured":"Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150(4):389\u2013405.","journal-title":"Br J Haematol"},{"issue":"4","key":"873_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/1024533031000153621","volume":"8","author":"X Thomas","year":"2003","unstructured":"Thomas X, Le QH. Prognostic factors in adult acute lymphoblastic leukemia. Hematology. 2003;8(4):233\u201342.","journal-title":"Hematology."},{"issue":"6","key":"873_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health."},{"key":"873_CR22","unstructured":"Decision Support Unit- National Institute for Healthcare Excellence (NICE). Methods for population-adjusted indirect comparisons in submissions to NICE. 2018. http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wp-content\/uploads\/sites\/7\/2017\/05\/Population-adjustment-TSD-FINAL.pdf. Accessed 24 Apr 2018"},{"key":"873_CR23","doi-asserted-by":"crossref","unstructured":"Thom H, Jugl S, Palaka E, Jawla S, editors. Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals. In: ISPOR 21st Annual International Meeting 2016 May 2016; Washington DC.","DOI":"10.1016\/j.jval.2016.03.1723"},{"key":"873_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"873_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics. 2010;28(10):935\u201345.","journal-title":"PharmacoEconomics."},{"key":"873_CR26","first-page":"2092","volume-title":"Estimator: method of moments. Encyclopedia of statistical sciences","author":"KS Bowman","year":"1998","unstructured":"Bowman KS. Estimator: method of moments. Encyclopedia of statistical sciences. Hoboken: Wiley; 1998. p. 2092\u20138."},{"issue":"23","key":"873_CR27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood.V126.23.679.679","volume":"126","author":"G Martinelli","year":"2015","unstructured":"Martinelli G, et al. Complete molecular and hematologic response in adult patients with relapsed\/refractory (R\/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTRA). Blood. 2015;126(23):679.","journal-title":"Blood."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-0873-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-019-0873-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-0873-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T07:16:56Z","timestamp":1713597416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-019-0873-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-0873-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}